Featured Research

from universities, journals, and other organizations

Prostate Cancer Vaccine Is First To Increase Survival

Date:
March 2, 2005
Source:
University Of California, San Francisco
Summary:
For the first time, researchers have found that a novel immunologic therapy increases survival by nearly 18 percent in men with advanced prostate cancer that no longer responds to hormone therapy.

For the first time, researchers have found that a novel immunologic therapy increases survival by nearly 18 percent in men with advanced prostate cancer that no longer responds to hormone therapy.

Related Articles


The therapeutic cancer vaccine, called APC8015 (Provenge), is likely to become a new standard of care for patients with metastatic prostate cancer. The UCSF-led study is the first to demonstrate a survival benefit from immunologic therapies or vaccines in patients with advanced prostate cancer.

"We’re very pleased with the results. A therapy that prolongs life yet avoids the side effects of other therapeutic approaches is clearly attractive to patients and physicians alike," said Eric Small, MD, UCSF professor of medicine and urology and lead investigator of the study.

The study will be presented in Orlando, Florida, on Saturday, Feb. 19, at a prostate cancer symposium sponsored by the American Society of Clinical Oncology, the Prostate Cancer Foundation, the American Society for Therapeutic Radiology and Oncology, and the Society of Urologic Oncology.

Although the new agent is called a vaccine, it is not designed to prevent cancer. Rather, it uses the patient’s own immune system to recognize and attack existing cancer cells. APC8015 is designed to stimulate the immune system to attack cells that express prostatic acid phosphatase (PAP), a protein found on approximately 95% of prostate cancer cells.

APC8015 is produced by collecting blood from each patient, isolating the relevant immune cells, and stimulating those cells so that they recognize PAP as "foreign." The resulting product, APC8015, is administered as an intravenous infusion.

In this study, investigators randomized 127 men with asymptomatic metastatic prostate cancer that no longer responded to hormone therapy to receive the vaccine (82 men) or a placebo (45 men). Patients received three doses of the vaccine at two-week intervals, and were followed for three years.

Overall survival among patients receiving the vaccine was 25.9 months, compared to 22 months in the placebo group. Three years later, more than three times as many vaccine patients (34 percent) were still alive, compared to the placebo group (11 percent). Treatment was well-tolerated – fever and shaking were reported as the most common side effects, and generally disappeared within two days of vaccine administration.

Therapeutic vaccines are being studied in the treatment of other types of cancer including lymphoma, leukemia, and cancers of the brain, breast, lung, kidney, ovary, pancreas, colon, and rectum.

In 2004, 26,000 men in the US died of prostate cancer. Prostate cancer is the most often diagnosed non-skin cancer in the US and the third most-common cancer worldwide, according to the American Cancer Society. Of the 185,000 men diagnosed each year in the US, an estimated 10-15 percent already have metastatic disease at the time of diagnosis, and another estimated 20 percent will develop metastatic disease.


Story Source:

The above story is based on materials provided by University Of California, San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University Of California, San Francisco. "Prostate Cancer Vaccine Is First To Increase Survival." ScienceDaily. ScienceDaily, 2 March 2005. <www.sciencedaily.com/releases/2005/02/050222111915.htm>.
University Of California, San Francisco. (2005, March 2). Prostate Cancer Vaccine Is First To Increase Survival. ScienceDaily. Retrieved January 27, 2015 from www.sciencedaily.com/releases/2005/02/050222111915.htm
University Of California, San Francisco. "Prostate Cancer Vaccine Is First To Increase Survival." ScienceDaily. www.sciencedaily.com/releases/2005/02/050222111915.htm (accessed January 27, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, January 27, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Mistakes Should Serve a Lesson Says WHO

Ebola Mistakes Should Serve a Lesson Says WHO

AFP (Jan. 25, 2015) The World Health Organization&apos;s chief on Sunday admitted the UN agency had been caught napping on Ebola, saying it should serve a lesson to avoid similar mistakes in future. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Disneyland Measles Outbreak Spreads To 5 States

Disneyland Measles Outbreak Spreads To 5 States

Newsy (Jan. 24, 2015) Much of the Disneyland measles outbreak is being blamed on the anti-vaccination movement. The CDC encourages just about everyone get immunized. Video provided by Newsy
Powered by NewsLook.com
Growing Measles Outbreak Worries Calif. Parents

Growing Measles Outbreak Worries Calif. Parents

AP (Jan. 23, 2015) Public health officials are rushing to contain a measles outbreak that has sickened 70 people across 6 states and Mexico. The AP&apos;s Raquel Maria Dillon has more. (Jan. 23) Video provided by AP
Powered by NewsLook.com
Smart Wristband to Shock Away Bad Habits

Smart Wristband to Shock Away Bad Habits

Reuters - Innovations Video Online (Jan. 23, 2015) A Boston start-up is developing a wristband they say will help users break bad habits by jolting them with an electric shock. Ben Gruber reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

    Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins